[REVISION HISTORY]
Inclisiran efficacy and evolving LDL cholesterol treatments
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-09-03 17:03 UTC → 2026-09-08 17:16 UTC ·
added
removed
Inclisiran efficacy in and evolving LDL cholesterol reduction treatments
Research into the efficacy of inclisiran, a drug utilizing small interfering RNA (siRNA) technology to inhibit PCSK9 protein production, has demonstrated significant potential in reducing LDL cholesterol. An initial meta-analysis of nine randomized clinical trials involving over 6,300 participants found that inclisiran achieved an average LDL cholesterol reduction of approximately 49% compared to a placebo. The study noted that the drug’s infrequent dosing schedule—requiring an injection only once every six months after initial doses—could improve patient compliance compared to daily statin regimens. Subsequent findings Results from the Victorion-Challenge study, presented at the European Society of Cardiology Congress, indicated that inclisiran outperformed bempedoic acid (ESC) Congress in Munich, further established inclisiran’s efficacy in patients with high or very high cardiovascular risk. risk from atherosclerotic cardiovascular disease (Ascvd). In this phase IV IV, randomized, open-label study, the inclisiran group saw a mean LDL-C reduction of 56.31% at day 150, whereas compared to a 15.35% reduction in the bempedoic acid group saw a reduction group. Notably, 78.2% of 15.35%. While patients treated with inclisiran showed higher reached their target LDL-C levels, while only 20.3% of those on bempedoic acid achieved the same goal. Despite these differences in efficacy, the frequency of treatment-related adverse events remained was similar between the two groups. groups, reported at 63.1% for inclisiran and 59.8% for bempedoic acid. The landscape for cholesterol management is expanding with the FDA approval of Lipfendra (enlicitide), the first oral PCSK9 inhibitor. Expected to be available by 2026, this medication provides an oral alternative to injectable treatments for high-risk adults.
Versions
- 2026-09-08 17:16 UTC Inclisiran efficacy and evolving LDL cholesterol treatments
- 2026-09-03 17:03 UTC Inclisiran efficacy in LDL cholesterol reduction
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.